Atezolizumab Approaches EU Approval for NSCLC, Urothelial Carcinoma
July 21, 2017 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has taken a positive position on indications for atezolizumab in non–small cell lung cancer (NSCLC) and urothelial carcinoma. Roche announced that the CHMP supports ...Leggi tutto